Description
1-Deoxymannojirimycin is a specific inhibitor of class I α-1,2-mannosidase (IC
50 = 0.02 μM), a key enzyme for N-glycan processing in the endoplasmic reticulum and Golgi and for targeting misfolded proteins for translocation out of the endoplasmic reticulum and degradation by the proteasome. By inhibiting α-1,2-mannosidase activity, this compound generates N-linked oligosaccharides with high mannose content, preventing misfolded protein degradation. This compound has been used for studies on glycoprotein processing and as a model for the development of anticancer and antiviral therapies.
Uses
Deoxymannojirimycin has been shown to be a potent inhibitor of the mammalian Golgi alpha- mannosidase 1 activity, blocking the conversion of high-mannose oligosaccharides to complex-type oligosaccharides. However, it does not inhibit the biosynthesis of lipid- linked oligosaccharides.
References
[1] J BISCHOFF R K L Liscum. The use of 1-deoxymannojirimycin to evaluate the role of various alpha-mannosidases in oligosaccharide processing in intact cells.[J]. The Journal of Biological Chemistry, 1986, 261 10: 4766-4774.
[2] JOYCE BISCHOFF Rosalind K. The effect of 1-deoxymannojirimycin on rat liver α-mannosidases[J]. Biochemical and biophysical research communications, 1984, 125 1: Pages 324-331. DOI:
10.1016/s0006-291x(84)80371-x[3] ULRIKE FUHRMANN. Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides[J]. Nature, 1984, 307 5953: 755-758. DOI:
10.1038/307755a0[4] KUNIO MIYAKE Kaoru N. Inhibition of α-mannosidase attenuates endoplasmic reticulum stress-induced neuronal cell death[J]. Neurotoxicology, 2009, 30 1: Pages 144-150. DOI:
10.1016/j.neuro.2008.10.010[5] APRIL TAI. Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells.[J]. Journal of Biological Engineering, 2011, 5 1: 1. DOI:
10.1186/1754-1611-5-1[6] CHI-LIN LEE. Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination[J]. Biotechnology and Bioengineering, 2011, 109 6: 1551-1560. DOI:
10.1002/bit.24413
